arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

MYRIAD GENETICS INC

MYGN
$3.25 ▲ +0.07 (+2.36%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
72 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

MYRIAD GENETICS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $308.1M
Dividend Yield
Revenue Growth -10.5%
Op. Margin -20.4%
ROIC -9.3%
FCF / Share $-0.09
Trailing P/E
Price / Book 1.0x
FCF Yield
Debt / Equity 0.40
info Valuation on last close. End-of-day price, Aug 7, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$190.70M
↓ -10.5%
Net Income Profit after all expenses
$-34.10M
↓ -34000.0%
Operating Margin Operating profit as % of sales
-20.4%
↓ -33.2% 5th
FCF / Share Free cash flow per share
$-0.09
↑ +47.7%
Long-Term Debt Long-term obligations
$120.70M
— +0.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
12
Returns
9
Financial Health
40
Cash Quality
22

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 72 quarters